Oral ixazomib-dexamethasone versus oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma (MM) patients: A global, multicenter, randomized, open-label, phase 2 trial.

Meletios A. Dimopoulos,Fredrik Schjesvold,Vadim A. Doronin,Olga Vinogradova,Hang Quach,Xavier Leleu,Gonzalez montes Yolanda,Karthik Ramasamy,Alessandra Pompa,Mark-David Levin,Cindy Lee,Ulf-Henrik Mellqvist,Roland Fenk,Hamdi Sati,Alexander Vorog,Richard Labotka,Jichang Du,Mohamed Darif,Shaji Kumar

Oral ixazomib-dexamethasone versus oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma (MM) patients: A global, multicenter, randomized, open-label, phase 2 trial.

2021

Meletios A. Dimopoulos
Fredrik Schjesvold
Vadim A. Doronin
Olga Vinogradova
Hang Quach
Xavier Leleu
Gonzalez montes Yolanda
Karthik Ramasamy
Alessandra Pompa
Mark-David Levin
Cindy Lee
Ulf-Henrik Mellqvist
Roland Fenk
Hamdi Sati
Alexander Vorog
Richard Labotka
Jichang Du
Mohamed Darif
Shaji Kumar

8020Background: MM patients (pts) often receive several lines of therapy with multiple drug combinations and, as lenalidomide (R)-containing regimens are commonly used as first-line therapy, R-free...

Keywords:

Lenalidomide
Medicine
Drug
Pomalidomide
Pharmacology
Ixazomib
Dexamethasone
Refractory
Proteasome inhibitor
Multiple myeloma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations